⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448145 | 0.72 | — | — | |
| SCHEMBL3547102 | 0.67 | — | — | |
| SCHEMBL1992561 | 0.67 | — | — | |
| SCHEMBL5133248 | 0.65 | — | — | |
| SCHEMBL15768107 | 0.64 | CYP1A2 (0.33) | — | |
| SCHEMBL11758822 | 0.58 | — | — | |
| SCHEMBL432350 | 0.58 | — | — | |
| SCHEMBL4305581 | 0.58 | — | — | |
| SCHEMBL1984014 | 0.58 | — | — | |
| SCHEMBL14671715 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544613-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-09 | — | — | EP | claimed |
| US-10752609-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-25 | — | — | US | claimed |
| US-20190315714-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | claimed |
| EP-3544613-A1 | GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-10-02 | — | — | EP | claimed |
| WO-2018098412-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | claimed |
| EP-3066093-B9 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-02-07 | — | — | EP | claimed |
| EP-3066093-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-04 | — | — | EP | claimed |
| US-9718804-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-01 | — | — | US | claimed |
| US-20160272621-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-22 | — | — | US | claimed |
| EP-3066093-A1 | GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-09-14 | — | — | EP | claimed |
| WO-2015069594-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-14 | — | — | WO | claimed |
| CN-1118467-C | 1,3,8-triaza-spiro [4,5] decan-4-on derivatives | HOFFMANN LA ROCHE (CH) | 2003-08-20 | — | — | CN | claimed |
| EP-0921125-A1 | 1,3,8-Triaza-spiro 4,5 decan-4-on derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-09 | — | — | EP | claimed |
| CN-86106435-A | Imidazolinyl derivative, its preparation method and the preparation that contains this compounds with herbicide effect | — | 1987-05-27 | — | — | CN | claimed |
| EP-3544613-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10752609-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190315714-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| EP-0921125-A1 | 1,3,8-Triaza-spiro 4,5 decan-4-on derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-09 | — | — | EP | disclosed |
| EP-0921125-A1 | 1,3,8-Triaza-spiro 4,5 decan-4-on derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-09 | — | — | EP | disclosed |
| CN-86106435-A | Imidazolinyl derivative, its preparation method and the preparation that contains this compounds with herbicide effect | — | 1987-05-27 | — | — | CN | disclosed |